Table 2
Marker expression in the six study groups
| Marker | Normal SCJ no inflammation | Normal SCJ with inflammation | BO | OAC | SSBO | IMNSCJ |
|---|---|---|---|---|---|---|
| Mean score (range; percentage + or more). | ||||||
| BO, Barrett’s oesophagus; IMNSCJ, intestinal metaplasia at a normal squamo–columnar junction; OAC, oesophageal adenocarcinoma; SCJ, squamo–columnar junction; SSBO, short segment Barrett’s oesophagus. | ||||||
| p21 | 0.3 (0–1; 25%) | 0.6 (0–2; 57%) | 0.3 (0–1; 25%) | 0.8 (0–2; 58%) | 0.6 (0–2; 50%) | 0.5 (0–2; 43%) |
| p27 | 0.4 (0–1; 42%) | 0.6 (0–1; 64%) | 0.3 (0–1; 25%) | 1.1 (0–2; 92%) | 0.7 (0–2; 60%) | 1.0 (0–2; 71%) |
| p53 | 0.1 (0–1; 8%) | 0.2 (0–1; 21%) | 0.1 (0–1; 8%) | 1.5 (0–3; 67%) | 0.4 (0–1; 40%) | 0.5 (0–2; 43%) |
| Ki67 | 0.4 (0–1; 42%) | 0.9 (0–2; 71%) | 0.3 (0–1; 25%) | 1.5 (0–3; 83%) | 0.6 (0–1; 60%) | 0.6 (0–1; 57%) |
| Cyclin D1 | 0.5 (0–1; 50%) | 0.5 (0–2; 36%) | 0.3 (0–2; 18%) | 0.7 (0–2; 58%) | 0.4 (0–1; 40%) | 1.0 (0–2; 79%) |
| c-erbB-2 | 0.5 (0–2; 42%) | 0.5 (0–1; 46%) | 0.9 (0–2; 67%) | 1.2 (0–3; 64%) | 0.7 (0–2; 50%) | 0.8 (0–2; 62%) |
